Titles
- Prescription drugs: U.S. prices for selected brand drugs were higher on average than prices in Australia, Canada, and France : report to the Chairman, Committee on the Budget, U.S. Senate1
- Prescription drugs: spending, use, and prices1
- Price decreases for widely used generic drugs slow in 2017 after two years of substantial price drops1
- Price increases for prescription drugs: 2016-20221
- Prices for and spending on specialty drugs in Medicare Part D and Medicaid1
- Prices for and spending on specialty drugs in Medicare Part D and Medicaid: an in-depth analysis1
- Rebates for brand-name drugs in Part D substantially reduced the growth in spending from 2011 to 20151
- Rx Watchdog report: comparative measures of price change for prescription drugs and other goods1
- Rx price watch report: price growth for brand name and specialty drugs more than offset price decrease for generic drugs1
- Rx price watch report: specialty prescription drug prices continue to climb1
- Rx price watch report: trends in retail prices of brand name prescription drug widely used by Medicare beneficiaries : 2005 to 20091
- Rx price watch report: trends in retail prices of generic prescription drugs widely used by Medicare beneficiaries : 2005 to 20091
- Rx price watch report: trends in retail prices of prescription drugs widely used by Medicare beneficiaries : 2005 to 20091
- Rx price watch report: trends in retail prices of specialty prescription drugs widely used by Medicare beneficiaries : 2005 to 20091
- Rx watchdog report: brand name drug prices continue to climb despite low general inflation rate1
- Rx watchdog report: drug prices continue to climb despite lack of growth in general inflation rate1
- Rx watchdog report: trends in manufacturer prices of prescription drugs used by Medicare beneficiaries, 2008 year-end update1
- Searching for savings in Medicare drug price negotiations1
- Spending on shoppable services in health care1
- Status of U.S. health insurance coverage and the potential of recent congressional health reform bills to expand coverage and lower consumer costs: invited testimony : U.S. House of Representatives, Committee on Rules : hearing on "Medicare for All Act of 2019"1